

Cardiac Troponin Market Report and Forecast 2024-2032

Market Report | 2024-09-30 | 200 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$4999.00
- Five User License \$5999.00
- Corporate License \$6999.00

Report description:

Global Cardiac Troponin Market Report and Forecast 2024-2032??

The global cardiac troponin market was valued at approximately USD 3 billion in 2023. The market is projected to grow at a CAGR of 8.2% from 2024 to 2032, reaching an estimated value of around USD 6.1 billion by 2032. This growth is driven by the rising cases of heart failure, advancements in diagnostic technologies, and increased demand for precise cardiac health monitoring, supported by healthcare investments and technological innovations.

Global Cardiac Troponin Market- Analysis

The global cardiac troponin market is witnessing substantial growth due to advancements in medical technologies and increasing prevalence of cardiovascular diseases. Cardiac troponin is a critical biomarker for diagnosing heart attacks and other cardiac conditions, making it essential in emergency and routine diagnostic settings. The demand for accurate and early diagnosis of cardiac events is further driving market growth.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Market Driver

Advancements in Diagnostic Technologies: Continuous innovations in diagnostic tools and assays have significantly enhanced the sensitivity and specificity of cardiac troponin tests. These advancements are driving market growth as healthcare providers seek more reliable and faster diagnostic solutions for cardiac events.

Rising Prevalence of Cardiovascular Diseases: The increasing incidence of heart diseases, such as acute coronary syndrome, myocardial infarction, and congestive heart failure, is fueling the demand for cardiac troponin tests. The aging population and lifestyle-related risk factors contribute to the growing number of cardiovascular cases, necessitating effective diagnostic tools.

Increased Demand for Precise Cardiac Health Monitoring: There is a growing emphasis on accurate and timely diagnosis of cardiac conditions to improve patient outcomes. Cardiac troponin tests provide crucial information for managing heart diseases, making them indispensable in clinical practice. The demand for precise cardiac health monitoring is driving the adoption of troponin assays.

Supportive Healthcare Investments: Government initiatives and investments in healthcare infrastructure are promoting the

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

development and adoption of advanced diagnostic solutions. Supportive policies and financial incentives for innovation in cardiac diagnostics are contributing to market growth, ensuring better access to troponin tests.

Market Challenges

High Costs of Advanced Diagnostic Tools: The high cost associated with advanced cardiac troponin tests and instruments can limit accessibility, particularly in cost-sensitive healthcare environments. This financial barrier is a significant challenge for widespread adoption.

Regulatory and Reimbursement Issues: Stringent regulatory requirements and reimbursement challenges can hinder market growth. Navigating complex approval processes and securing adequate reimbursement for advanced diagnostic tests can be time-consuming and costly for manufacturers and healthcare providers.

Limited Awareness in Developing Regions: The limited awareness and understanding of cardiac troponin tests in developing regions can hinder market growth. Increasing knowledge about the importance of early diagnosis and the availability of advanced diagnostic tools through educational initiatives is essential to promoting wider adoption.

Future Opportunities

Expansion into Emerging Markets: Expanding into emerging markets with improving healthcare infrastructure presents substantial growth opportunities. These regions offer untapped potential for increasing access to cardiac troponin tests and improving patient outcomes.

Development of Novel Diagnostic Solutions: The development of novel diagnostic solutions, such as high-sensitivity troponin assays and point-of-care testing devices, can enhance the accuracy and convenience of cardiac diagnostics. Innovations in diagnostic technologies are expected to drive market growth by providing more efficient and reliable solutions.

Collaborations and Partnerships: Strategic partnerships between diagnostic companies, healthcare providers, and research institutions can drive market expansion. Collaborations can facilitate research, development, and distribution efforts, enhancing the availability and quality of cardiac troponin tests.

Integration with Advanced Technologies: Incorporating advanced technologies, such as artificial intelligence and machine learning, can enhance the functionality and efficiency of cardiac troponin tests. These innovations can drive market growth by providing more accurate and personalized diagnostic solutions.

Global Cardiac Troponin Market Trends

Rising Adoption of Point-of-Care Testing: The adoption of point-of-care testing (POCT) for cardiac biomarkers is increasing due to their effectiveness in providing rapid diagnostic results. POCT allows for immediate decision-making in emergency settings, which is crucial for acute cardiac events. This trend is driving market growth as more healthcare providers incorporate POCT into their diagnostic protocols, improving patient outcomes through timely interventions.

Focus on High-Sensitivity Troponin Assays: There is a growing trend towards the use of high-sensitivity troponin assays in clinical practice. These assays offer improved diagnostic accuracy and early detection of cardiac events, which is vital for preventing complications and initiating early treatment. High-sensitivity assays are becoming the standard of care, enhancing patient care and supporting market growth by providing more reliable and actionable diagnostic information.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Increased Investment in R&D: Investment in research and development for cardiac troponin tests is on the rise. Companies are dedicating significant resources to discovering new diagnostic applications and improving existing tests, fostering innovation in the market. This includes developing more sensitive and specific assays, integrating advanced technologies like AI for better analysis, and exploring new biomarkers that can complement troponin testing, thereby expanding the scope of cardiac diagnostics.

Emphasis on Preventive Care: Ensuring preventive care in cardiac health is a top priority. Advances in diagnostic technologies are enabling early detection and intervention, reducing the incidence of severe cardiac events. Preventive care strategies, supported by regular monitoring and early diagnosis through advanced troponin tests, are driving market growth. This emphasis on preventive care is expected to continue driving innovation and adoption in cardiac diagnostics, ultimately improving long-term patient outcomes.

Global Cardiac Troponin Market Segmentation

Market Breakup by Product Type

Instrument

Kits and Reagents

The global cardiac troponin market is segmented by product type into instruments and kits & reagents. Instruments include diagnostic machines and analyzers used in laboratories and healthcare facilities, essential for performing troponin tests with high precision and accuracy. Kits and reagents are crucial for conducting these tests and are widely used in various clinical settings. The demand for these products is driven by the need for reliable and rapid diagnostic tools, with kits and reagents being indispensable for routine and emergency testing.

Market Breakup by Type

Troponin T

Troponin I

The market is segmented by type into Troponin T and Troponin I. Both types are critical biomarkers for diagnosing cardiac events, with Troponin I being more specific to myocardial injury. Troponin T is often used in conjunction with other tests for a comprehensive assessment. The choice between Troponin T and Troponin I depends on the clinical setting and the specific requirements of the diagnostic test, with both playing significant roles in enhancing diagnostic accuracy and patient care.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Market Breakup by Application

Acute Coronary Syndrome

Myocardial Infarction

Congestive Heart Failure

Others

The market is segmented by application into acute coronary syndrome, myocardial infarction, congestive heart failure, and others. Acute coronary syndrome and myocardial infarction are the primary applications due to their high prevalence and need for immediate diagnosis. Congestive heart failure and other cardiac conditions also significantly contribute to the demand for troponin tests, as early and accurate diagnosis is critical for effective management and treatment, reducing the risk of complications and improving patient outcomes.

Market Breakup by End User

Hospitals

Diagnostic Centres

Homecare Settings

Others

The market is segmented by end user into hospitals, diagnostic centres, homecare settings, and others. Hospitals and diagnostic centres dominate the market due to the need for accurate and timely diagnosis of cardiac conditions. Homecare settings are also gaining importance with the rise of point-of-care testing devices that allow for monitoring at home. This shift towards homecare is driven by the increasing demand for convenient and accessible healthcare solutions, enabling patients to manage their conditions more effectively and reducing the burden on healthcare facilities.

Market Breakup by Region

North America?

Europe

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Asia Pacific

Latin America

Middle East and Africa

The global cardiac troponin market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America and Europe lead the market due to advanced healthcare infrastructure and high adoption of new diagnostic technologies. Asia Pacific and Latin America are emerging as significant growth areas, driven by improving healthcare access, increasing awareness about cardiac health, and the rising prevalence of cardiovascular diseases. The Middle East and Africa also offer substantial opportunities for market expansion, with growing investments in healthcare infrastructure and an increasing focus on early diagnosis and preventive care.

Cardiac Troponin Market Competitive Landscape

The global cardiac troponin market features several key players actively shaping the competitive landscape. Notable companies include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Beckman Coulter, Inc., Creative Diagnostics, bioMerieux SA, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Danaher Corporation, Randox Laboratories Ltd, and Eurolyser Diagnostica GmbH. These companies engage in activities such as mergers and acquisitions, research initiatives, product introductions, and strategic partnerships to expand their market presence and capabilities. These activities drive innovation and growth within the cardiac troponin market, ensuring continuous improvement and broadening service offerings.

Key Questions Answered in the Report

What is the projected CAGR for the global cardiac troponin market during the forecast period 2024-2032?

How are advancements in diagnostic technologies influencing the growth of the cardiac troponin market?

What factors are contributing to the increasing prevalence of cardiovascular diseases globally?

How is the rising demand for precise cardiac health monitoring impacting the market for cardiac troponin tests?

What role do government initiatives and healthcare investments play in driving the cardiac troponin market?

What are the main challenges associated with the high costs of advanced cardiac troponin diagnostic tools?

How do regulatory and reimbursement issues affect the adoption of cardiac troponin tests?

What opportunities exist for expanding the cardiac troponin market into emerging regions?

How is the development of novel diagnostic solutions expected to influence the market for cardiac troponin tests?

In what ways are collaborations and partnerships shaping the growth and innovation in the cardiac troponin market?

How does the rising adoption of point-of-care testing for cardiac biomarkers drive market growth?

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

What impact does the emphasis on preventive care have on the adoption and innovation of cardiac troponin diagnostics?

Key Benefits for Stakeholders

The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the cardiac troponin market from 2017-2032.

The research report provides the latest information on the market drivers, challenges, and opportunities in the cardiac troponin market.

The study maps the leading, as well as the fastest-growing, regional markets, enabling stakeholders to identify key country-level markets within each region.

Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the cardiac troponin industry and its attractiveness.

The competitive landscape section allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

Table of Contents:

- 1□Preface
- 1.1□Objectives of the Study
- 1.2□Key Assumptions
- 1.3□Report Coverage - Key Segmentation and Scope

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 1.4□Research Methodology
- 2□Executive Summary
- 3□Global Cardiac Troponin Market Overview
- 3.1□Global Cardiac Troponin Market Historical Value (2017-2023)
- 3.2□Global Cardiac Troponin Market Forecast Value (2024-2032)
- 4□Vendor Positioning Analysis
- 4.1□Key Vendors
- 4.2□Prospective Leaders
- 4.3□Niche Leaders
- 4.4□Disruptors
- 5□Global Cardiac Troponin Market Landscape*
- 5.1□Global Cardiac Troponin Market: Developers Landscape
- 5.1.1□Analysis by Year of Establishment
- 5.1.2□Analysis by Company Size
- 5.1.3□Analysis by Region
- 5.2□Global Cardiac Troponin Market: Product Landscape
- 5.2.1□Analysis by Type
- 5.2.2□Analysis by Product Type
- 5.2.3□Analysis by Application
- 6□Global Cardiac Troponin Market Dynamics
- 6.1□Market Drivers and Constraints
- 6.2□SWOT Analysis
- 6.2.1□Strengths
- 6.2.2□Weaknesses
- 6.2.3□Opportunities
- 6.2.4□Threats
- 6.3□PESTEL Analysis
- 6.3.1□Political
- 6.3.2□Economic
- 6.3.3□Social
- 6.3.4□Technological
- 6.3.5□Legal
- 6.3.6□Environment
- 6.4□Porter's Five Forces Model
- 6.4.1□Bargaining Power of Suppliers
- 6.4.2□Bargaining Power of Buyers
- 6.4.3□Threat of New Entrants
- 6.4.4□Threat of Substitutes
- 6.4.5□Degree of Rivalry
- 6.5□Key Demand Indicators
- 6.6□Key Price Indicators
- 6.7□Industry Events, Initiatives, and Trends
- 6.8□Value Chain Analysis
- 7□Global Cardiac Troponin Market Segmentation (2017-2032)
- 7.1□Global Cardiac Troponin Market (2017-2032) by Product Type
- 7.1.1□Market Overview
- 7.1.2□Instrument

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.1.3 Kits and Reagents
- 7.2 Global Cardiac Troponin Market (2017-2032) by Type
 - 7.2.1 Market Overview
 - 7.2.2 Troponin T
 - 7.2.3 Troponin I
- 7.3 Global Cardiac Troponin Market (2017-2032) by Application
 - 7.3.1 Market Overview
 - 7.3.2 Acute Coronary Syndrome
 - 7.3.3 Myocardial Infarction
 - 7.3.4 Congestive Heart Failure
 - 7.3.5 Others
- 7.4 Global Cardiac Troponin Market (2017-2032) by End User
 - 7.4.1 Market Overview
 - 7.4.2 Hospitals
 - 7.4.3 Diagnostic Centres
 - 7.4.4 Homecare Settings
 - 7.4.5 Others
- 7.5 Global Cardiac Troponin Market (2017-2032) by Region
 - 7.5.1 Market Overview
 - 7.5.2 North America
 - 7.5.3 Europe
 - 7.5.4 Asia Pacific
 - 7.5.5 Latin America
 - 7.5.6 Middle East and Africa
- 8 North America Cardiac Troponin Market (2017-2032)
 - 8.1 North America Cardiac Troponin Market (2017-2032) by Product Type
 - 8.1.1 Market Overview
 - 8.1.2 Instrument
 - 8.1.3 Kits and Reagents
 - 8.2 North America Cardiac Troponin Market (2017-2032) by Type
 - 8.2.1 Market Overview
 - 8.2.2 Troponin T
 - 8.2.3 Troponin I
 - 8.3 North America Cardiac Troponin Market (2017-2032) by Application
 - 8.3.1 Market Overview
 - 8.3.2 Acute Coronary Syndrome
 - 8.3.3 Myocardial Infarction
 - 8.3.4 Congestive Heart Failure
 - 8.3.5 Others
 - 8.4 North America Cardiac Troponin Market (2017-2032) by End User
 - 8.4.1 Market Overview
 - 8.4.2 Hospitals
 - 8.4.3 Diagnostic Centres
 - 8.4.4 Homecare Settings
 - 8.4.5 Others
 - 8.5 North America Cardiac Troponin Market (2017-2032) by Country
 - 8.5.1 United States of America

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.5.2 Canada
- 9 Europe Cardiac Troponin Market (2017-2032)
 - 9.1 Europe Cardiac Troponin Market (2017-2032) by Product Type
 - 9.1.1 Market Overview
 - 9.1.2 Instrument
 - 9.1.3 Kits and Reagents
 - 9.2 Europe Cardiac Troponin Market (2017-2032) by Type
 - 9.2.1 Market Overview
 - 9.2.2 Troponin T
 - 9.2.3 Troponin I
 - 9.3 Europe Cardiac Troponin Market (2017-2032) by Application
 - 9.3.1 Market Overview
 - 9.3.2 Acute Coronary Syndrome
 - 9.3.3 Myocardial Infarction
 - 9.3.4 Congestive Heart Failure
 - 9.3.5 Others
 - 9.4 Europe Cardiac Troponin Market (2017-2032) by End User
 - 9.4.1 Market Overview
 - 9.4.2 Hospitals
 - 9.4.3 Diagnostic Centres
 - 9.4.4 Homecare Settings
 - 9.4.5 Others
 - 9.5 Europe Cardiac Troponin Market (2017-2032) by Country
 - 9.5.1 United Kingdom
 - 9.5.2 Germany
 - 9.5.3 France
 - 9.5.4 Italy
 - 9.5.5 Others
- 10 Asia Pacific Cardiac Troponin Market (2017-2032)
 - 10.1 Asia Pacific Cardiac Troponin Market (2017-2032) by Product Type
 - 10.1.1 Market Overview
 - 10.1.2 Instrument
 - 10.1.3 Kits and Reagents
 - 10.2 Asia Pacific Cardiac Troponin Market (2017-2032) by Type
 - 10.2.1 Market Overview
 - 10.2.2 Troponin T
 - 10.2.3 Troponin I
 - 10.3 Asia Pacific Cardiac Troponin Market (2017-2032) by Application
 - 10.3.1 Market Overview
 - 10.3.2 Acute Coronary Syndrome
 - 10.3.3 Myocardial Infarction
 - 10.3.4 Congestive Heart Failure
 - 10.3.5 Others
 - 10.4 Asia Pacific Cardiac Troponin Market (2017-2032) by End User
 - 10.4.1 Market Overview
 - 10.4.2 Hospitals
 - 10.4.3 Diagnostic Centres

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.4.4□Homecare Settings
- 10.4.5□Others
- 10.5□Asia Pacific Cardiac Troponin Market (2017-2032) by Country
 - 10.5.1□China
 - 10.5.2□Japan
 - 10.5.3□India
 - 10.5.4□ASEAN
 - 10.5.5□Australia
 - 10.5.6□Others
- 11□Latin America Cardiac Troponin Market (2017-2032)
 - 11.1□Latin America Cardiac Troponin Market (2017-2032) by Product Type
 - 11.1.1□Market Overview
 - 11.1.2□Instrument
 - 11.1.3□Kits and Reagents
 - 11.2□Latin America Cardiac Troponin Market (2017-2032) by Type
 - 11.2.1□Market Overview
 - 11.2.2□Troponin T
 - 11.2.3□Troponin I
 - 11.3□Latin America Cardiac Troponin Market (2017-2032) by Application
 - 11.3.1□Market Overview
 - 11.3.2□Acute Coronary Syndrome
 - 11.3.3□Myocardial Infarction
 - 11.3.4□Congestive Heart Failure
 - 11.3.5□Others
 - 11.4□Latin America Cardiac Troponin Market (2017-2032) by End User
 - 11.4.1□Market Overview
 - 11.4.2□Hospitals
 - 11.4.3□Diagnostic Centres
 - 11.4.4□Homecare Settings
 - 11.4.5□Others
 - 11.5□Latin America Cardiac Troponin Market (2017-2032) by Country
 - 11.5.1□Brazil
 - 11.5.2□Argentina
 - 11.5.3□Mexico
 - 11.5.4□Others
- 12□Middle East and Africa Cardiac Troponin Market (2017-2032)
 - 12.1□Middle East and Africa Cardiac Troponin Market (2017-2032) by Product Type
 - 12.1.1□Market Overview
 - 12.1.2□Instrument
 - 12.1.3□Kits and Reagents
 - 12.2□Middle East and Africa Cardiac Troponin Market (2017-2032) by Type
 - 12.2.1□Market Overview
 - 12.2.2□Troponin T
 - 12.2.3□Troponin I
 - 12.3□Middle East and Africa Cardiac Troponin Market (2017-2032) by Application
 - 12.3.1□Market Overview
 - 12.3.2□Acute Coronary Syndrome

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.3.3 Myocardial Infarction
- 12.3.4 Congestive Heart Failure
- 12.3.5 Others
- 12.4 Middle East and Africa Cardiac Troponin Market (2017-2032) by End User
- 12.4.1 Market Overview
- 12.4.2 Hospitals
- 12.4.3 Diagnostic Centres
- 12.4.4 Homecare Settings
- 12.4.5 Others
- 12.5 Middle East and Africa Cardiac Troponin Market (2017-2032) by Country
- 12.5.1 Saudi Arabia
- 12.5.2 United Arab Emirates
- 12.5.3 Nigeria
- 12.5.4 South Africa
- 12.5.5 Others
- 13 Regulatory Framework
- 13.1 Regulatory Overview
- 13.2 US FDA
- 13.3 EU EMA
- 13.4 INDIA CDSCO
- 13.5 JAPAN PMDA
- 13.6 Others
- 14 Patent Analysis
- 14.1 Analysis by Type of Patent
- 14.2 Analysis by Publication Year
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Patent Age
- 14.5 Analysis by CPC Analysis
- 14.6 Analysis by Patent Valuation
- 14.7 Analysis by Key Players
- 15 Funding and Investment Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Type of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Strategic Initiatives
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape
- 17.1 Market Share Analysis, By Region (Top 5 Companies)
- 17.1.1 Market Share Analysis: Global
- 17.1.2 Market Share Analysis: North America
- 17.1.3 Market Share Analysis: Europe

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.1.4□Market Share Analysis: Asia Pacific
- 17.1.5□Market Share Analysis: Others
- 17.2□Abbott Laboratories
 - 17.2.1□Financial Analysis
 - 17.2.2□Product Portfolio
 - 17.2.3□Demographic Reach and Achievements
 - 17.2.4□Company News and Developments
 - 17.2.5□Certifications
- 17.3□F. Hoffmann-La Roche Ltd
 - 17.3.1□Financial Analysis
 - 17.3.2□Product Portfolio
 - 17.3.3□Demographic Reach and Achievements
 - 17.3.4□Company News and Developments
 - 17.3.5□Certifications
- 17.4□Beckman Coulter, Inc .
 - 17.4.1□Financial Analysis
 - 17.4.2□Product Portfolio
 - 17.4.3□Demographic Reach and Achievements
 - 17.4.4□Company News and Developments
 - 17.4.5□Certifications
- 17.5□Creative Diagnostics
 - 17.5.1□Financial Analysis
 - 17.5.2□Product Portfolio
 - 17.5.3□Demographic Reach and Achievements
 - 17.5.4□Company News and Developments
 - 17.5.5□Certifications
- 17.6□bioMérieux SA
 - 17.6.1□Financial Analysis
 - 17.6.2□Product Portfolio
 - 17.6.3□Demographic Reach and Achievements
 - 17.6.4□Company News and Developments
 - 17.6.5□Certifications
- 17.7□Thermo Fisher Scientific Inc .
 - 17.7.1□Financial Analysis
 - 17.7.2□Product Portfolio
 - 17.7.3□Demographic Reach and Achievements
 - 17.7.4□Company News and Developments
 - 17.7.5□Certifications
- 17.8□ Siemens Healthineers AG
 - 17.8.1□Financial Analysis
 - 17.8.2□Product Portfolio
 - 17.8.3□Demographic Reach and Achievements
 - 17.8.4□Company News and Developments
 - 17.8.5□Certifications
- 17.9□Danaher Corporation
 - 17.9.1□Financial Analysis
 - 17.9.2□Product Portfolio

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.9.3□Demographic Reach and Achievements
- 17.9.4□Company News and Developments
- 17.9.5□Certifications
- 17.10□Randox Laboratories Ltd
- 17.10.1□Financial Analysis
- 17.10.2□Product Portfolio
- 17.10.3□Demographic Reach and Achievements
- 17.10.4□Company News and Developments
- 17.10.5□Certifications
- 17.11□Eurolyser Diagnostica GmbH
- 17.11.1□Financial Analysis
- 17.11.2□Product Portfolio
- 17.11.3□Demographic Reach and Achievements
- 17.11.4□Company News and Developments
- 17.11.5□Certifications
- 18□Global Cardiac Troponin Market - Distribution Model (Additional Insight)
- 18.1□ Overview
- 18.2□ Potential Distributors
- 18.3□ Key Parameters for Distribution Partner Assessment
- 19□Key Opinion Leaders (KOL) Insights (Additional Insight)

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Cardiac Troponin Market Report and Forecast 2024-2032

Market Report | 2024-09-30 | 200 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4999.00
	Five User License	\$5999.00
	Corporate License	\$6999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-07"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com